A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

-Adult participants ≥ 18 years of age. -Participants or participant's legally authorized representative has provided informed consent to participate in this study. -Participants who meet one of the following: -Prescribed Repatha® in addition to an existing SOC treatment according to local guidelines and approved label. OR -Already received SOC treatment prior to enrollment. -Participants with ANY of the following. -Diagnosis of MI OR stroke within 2 years before enrollment. -2 MIs OR ≥ 2 strokes OR (≥ 1 MI AND ≥ 1 stroke) any time before enrollment. -Diagnosis of (MI OR stroke) AND diabetes. -Diagnosis of (MI OR stroke) AND documented multivessel disease (defined as > 50% stenosis of ≥ 2 major coronary arteries on coronary angiography or coronary artery contrast enhanced computed tomography). -Diagnosis of symptomatic peripheral arterial disease. -Most recent fasting LDL-C ≥ 70 mg/dL (≥ 1.8 mmol/L) or nonhigh-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL (≥ 2.6 mmol/L) within 6 months prior to enrollment. -Most recent fasting triglycerides ≤ 400 mg/dL (≤ 4.5 mmol/L) within 6 months prior to enrollment.

-Stroke within past 1 month. -Known hemorrhagic stroke at any time. -Stroke due to thromboembolic event. -Any prior use of Repatha® or other proprotein convertase subtilisin/kexin type 9 inhibition treatments within past 6 months prior to enrollment. -Participants currently enrolled in another study involving any investigational procedure, device or drug. -Participants prescribed Repatha® with a history of severe hypersensitivity or allergy to any subsidiary.